The ‘710 Patent, expiring in
“vTv is currently the only company developing a treatment for
Alzheimer’s disease by targeting the RAGE receptor, which has
demonstrated potential in addressing three key pathologies in
Alzheimer's disease: amyloid-β, tau and chronic inflammation,” said
Azeliragon is currently being studied in a randomized, double-blind,
placebo-controlled Phase 3 trial investigating the efficacy of
azeliragon as a potential treatment to slow the decline in cognition and
functional activities for patients with mild Alzheimer’s disease. Data
from Part A of the trial is expected to read out in late
About
The Company’s lead drug candidates were discovered with its high-throughput drug discovery platform, TTP Translational Technology®, which translates the functional modulation of human proteins into safe and effective medicines. For further company information, visit www.vtvtherapeutics.com.
Forward-Looking Statements
This release contains forward-looking statements, which involve risks
and uncertainties. These forward-looking statements can be identified by
the use of forward-looking terminology, including the terms
“anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,”
“plan,” “potential,” “predict,” “project,” “should,” “target,” “will,”
“would” and, in each case, their negative or other various or comparable
terminology. All statements other than statements of historical facts
contained in this release, including statements regarding the timing of
our clinical trials, our strategy, future operations, future financial
position, future revenue, projected costs, prospects, plans, objectives
of management and expected market growth are forward-looking statements.
These statements involve known and unknown risks, uncertainties and
other important factors that may cause our actual results, performance
or achievements to be materially different from any future results,
performance or achievements expressed or implied by the forward-looking
statements. Important factors that could cause our results to vary from
expectations include those described under the heading “Risk Factors” in
our Annual Report on Form 10-K and our other filings with the
View source version on businesswire.com: http://www.businesswire.com/news/home/20170803005121/en/
Source:
Investors
vTv Therapeutics Inc.
Michael Gibralter,
646-378-2938
IR@vtvtherapeutics.com
or
Media
Pure
Communications Inc.
Katie Engleman, 910-509-3977
Katie@purecommunications.com